FINWIRES · TerminalLIVE
FINWIRES

Lung Fung Group Raises HK$600 Million in Hong Kong IPO Ahead of Debut

By

Lung Fung Group (HKG:2290) raised HK$599.6 million in net proceeds from its initial public offering in Hong Kong.

The final offer price was set at HK$5.18 per share, the bottom of the offer price range, according to a Thursday after-market filing with the Hong Kong Stock Exchange.

The Hong Kong-based beauty, health, and pharmaceutical products retailer offered 125 million shares in the global offering.

The Hong Kong public offer was 664.92 times subscribed, with a final allocation of 12.5 million shares, representing 10% of the total offering.

The international offering was 3.18 times subscribed, with a final allocation of 112.5 million shares, or 90% of the total offering.

Lung Fung Group is scheduled to debut on the Hong Kong bourse on Friday, June 5.

Related Articles

Asia

Gentrack Group Says Regal Partners' Unit Reduces Stake

Gentrack Group (ASX:GTK, NZE:GTK) received notice that Regal Funds Management, a unit of Regal Partners (ASX:RPL), decreased its holdings in the company to 8.748% from 9.79%, according to a Friday filing with the New Zealand bourse.Regal Funds now owns 9.8 million shares in the company, the filing said.

$ASX:GTK$ASX:RPL$NZE:GTK
Asia

Meridian Energy 'Welcomes' Draft Fast-Track Decision to Relax Lake Pukaki Water Limits

Meridian Energy (NZE:MEL, ASX:MEZ) "welcomed" a fast-track panel draft decision to relax operating limits at Lake Pukaki, allowing use of water stored between 518 and 513 meters above sea level for three years, ahead of a Transpower-estimated 4% electricity shortage risk threshold, according to a Friday filing with the Australian and New Zealand bourses.The company acknowledged stakeholder concerns regarding eased access to contingent storage and proposes that, if the draft is confirmed, half of the five meters of contingent storage continue to be restricted to periods of heightened supply security risk for the remainder of the year, given the positive hydro outlook for winter, the filing said.The draft decision also approves permanent rock armoring at Pukaki Dam to improve resilience against wave erosion under lower lake operating levels.The panel's final decision is due by July 3, the filing added.

$ASX:MEZ$NZE:MEL
Asia

LongBio Pharma Raises HK$1.3 Billion in Hong Kong IPO Ahead of Debut

LongBio Pharma (HKG:1779) raised HK$1.25 billion in net proceeds from its initial public offering in Hong Kong.The final offer price was set at HK$96.06 per H-share, according to a Thursday after-market filing with the Hong Kong Stock Exchange.The Chinese biopharmaceutical company offered 14.2 million H-shares in the global offering.The Hong Kong public offer was 4,762.58 times subscribed, with a final allocation of 1.4 million shares, representing 10% of the total offering.The international offering was 10.94 times subscribed, with a final allocation of 12.8 million shares, or 90% of the total offering.An over-allocation of 2.1 million shares was made under the global offering.Cornerstone investors, including OrbiMed Genesis, The Biotech Growth Trust, TruMed Innovation Fund, TruMed Master Fund, Shanghai Gaoyi, Wisdomshire Asset Management, Vision Fund 1, and GSC Fund 1, were allotted a combined 7.1 million shares, representing 49.96% of the global offering, according to the filing.LongBio Pharma is set to debut on the Hong Kong bourse on Friday, June 5.

$HKG:1779